Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Interest Expenses (2019 - 2022)

Historic Interest Expenses for Keros Therapeutics (KROS) over the last 4 years, with Q1 2022 value amounting to $1000.0.

  • Keros Therapeutics' Interest Expenses changed 0.0% to $1000.0 in Q1 2022 from the same period last year, while for Dec 2022 it was $1000.0, marking a year-over-year decrease of 7500.0%. This contributed to the annual value of $1000.0 for FY2022, which is 7500.0% down from last year.
  • Latest data reveals that Keros Therapeutics reported Interest Expenses of $1000.0 as of Q1 2022, which was down 0.0% from $1000.0 recorded in Q4 2021.
  • Keros Therapeutics' 5-year Interest Expenses high stood at $3000.0 for Q3 2019, and its period low was $1000.0 during Q2 2020.
  • Moreover, its 4-year median value for Interest Expenses was $1000.0 (2020), whereas its average is $1500.0.
  • Examining YoY changes over the last 5 years, Keros Therapeutics' Interest Expenses showed a top increase of 0.0% in 2020 and a maximum decrease of 5000.0% in 2020.
  • Over the past 4 years, Keros Therapeutics' Interest Expenses (Quarter) stood at $3000.0 in 2019, then tumbled by 66.67% to $1000.0 in 2020, then changed by 0.0% to $1000.0 in 2021, then changed by 0.0% to $1000.0 in 2022.
  • Its last three reported values are $1000.0 in Q1 2022, $1000.0 for Q4 2021, and $1000.0 during Q3 2021.